The TRANSVAC Annual Meeting successfully took place on 6-7 September in Frankfurt (DE), including sessions on both TRANSVAC2 and TRANSVAC-DS. The team had the opportunity to meet in person and it was a great opportunity to discuss and define the next steps towards a sustainable European vaccine R&D infrastructure.
Thank you to all participants for their long-term collaboration in supporting the present and transforming the future of vaccine R&D landscape in Europe, while creating global (health) impact.
Comments